Rapport Therapeutics (RAPP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Rapport Therapeutics (RAPP) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.46 of bullish evidence against -0.27 bearish.

Rapport Therapeutics last closed at $31.15, -3.23% on the session.

Against the IVW growth benchmark the position is -3.84% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

4 graded predictions for RAPP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Rapport Therapeutics in the 24th percentile on return on equity, where 100 is best.

Rapport Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.54B.

StockMap tracks Rapport Therapeutics as the 48th largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite Rapport Therapeutics ranks 70th of 142 in the group, against a group median of -0.24.